Plan B: What Came Before, Where It Can Go And What It All Means
This article was originally published in The Tan Sheet
Executive Summary
Barr Labs appears to have no legal recourse following FDA's failure to meet the PDUFA deadline for the firm's Plan B emergency contraceptive switch if the agency chooses to delay a decision on the application indefinitely
You may also be interested in...
NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting
Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.
Plan B Decision Expected In Coming Weeks, Barr CEO Says
Downey says Rx sales of approximately $20 mil. have restricted availability of the emergency contraceptive at pharmacies across the country.
Topical Corticosteroid Adrenal Suppression Risk Precludes OTC Use, Advisory Committe Says
Topical corticosteroid HPA axis suppression risk under "maximal use conditions" should preclude the OTC marketing of the dermatologic products, FDA advisory committees say. Test for hypothalamus, pituitary, adrenal axis suppression is only 70% accurate, committee members note.